Management of Kaposi sarcoma: The role of interferon and thalidomide

Current Opinion in Oncology

Volumn 13, Issue 5, 2001, Pages 374-381

  Krown, Susan E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INTERFERON; THALIDOMIDE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EFFECTOR CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

ANTIVIRAL AGENTS; COMBINED MODALITY THERAPY; CYTOKINES; DISEASE PROGRESSION; HIV INFECTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-ALPHA; SARCOMA, KAPOSI; THALIDOMIDE;

EID: 0034872059     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200109000-00010     Document Type: Review

References (123)

1. Centers for Disease Control Kaposi's sarcoma, and Pneumocystis pneumonia among homosexual men: New York City and California
2. Incidence and trends in Kaposi's sarcoma in the era of effective antiretroviral therapy
3. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. Multicenter AIDS Cohort Study
4. Kaposi's sarcoma-associated herpesvirus: A lymphotropic human herpesvirus associated with Kaposi's sarcoma, primary effusion lymphoma, and multicentric Casfieman's disease
5. Development of Kaposi sarcoma despite sustained suppression of HW plasma viremia
6. Kaposi's sarcoma in South Africa
7. Acquired immunodeficiency syndrome-associated cancers in sub-Saharan Africa
8. Cancer incidence in the African population of Harare, Zimbabwe: Second results from the cancer registry 1993-1995
9. Cancer incidence in Abidjan, Ivory Coast: First results from the cancer registry, 1995-1997
10. AIDS-related cancers in Africa: Maturation of the epidemic in Uganda
11. Trends in cancer incidence in Kyadondo County, Uganda, 1960-1997
12. Identification and culture of Kaposi's sarcoma-like spindle Cells from the peripheral blood of human immunedeficiency virus-1-infected individuals and normal controls
13. The histogenesis of Kaposi's sarcoma
14. Early lesions of Kaposi's sarcoma in homosexual men: An ultrastructural comparison with other vascular proliferations in skin
15. Macrophages and vascular adhesion molecules in oral Kaposi's sarcoma
16. Human immunodeficiency virus-associated oral Kaposi's sarcoma: A heterogeneous cell population deminated by spindle-shaped endothelial cells
17. Sexual transmission and the natural history of human herpesvirus 8 infection
18. Interassay correlation of human herpesvirus 8 serologic tests: HHV-8 Interlaboratory Collaborative Group
19. Kaposi's sarcoma-associated herpesvirus-encoded oncogenes and oncogenesis
20. Big but weak: How many pathogenic genes does human herpesvirus-8 need to cause Kaposi's sarcoma?
21. Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells
22. Monocytes in Kaposi's sarcoma lesions are productively infected by human herpesvirus-8
23. Visualization of human herpesvirus type 8 in Kaposi's sarcoma by light and transmission electron microscopy
24. Human herpesvirus 8 cellular immune responses in homosexual men
25. Identification of human herpesvirus 8-specific cytotoxic T-cell responses
26. Impaired CTL recognition of cells latently infected with Kaposi's sarcoma-associated herpes virus
27. AIDS Kaposi's sarcoma derived cells express cytokines with autocrine and paracrine growth effects
28. AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6
29. Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi's sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development
30. Expression of multiple matrix metallopro and urokinase type plasminogen activator in cultured Kaposi sarcoma cells
31. Inflammatory cytokines synergize with the HIV-1 Tat protein to promote angiogenesis and Kaposi's sarcoma via induction of basic fibroblast growth factor and the alpha v beta 3 integrin
32. IFN-gamma induces endothelial cells to proliferate and to invade the extracellular matrix in response to the HIV-1 Tat protein: Implications for AIDS-Kaposi's sarcoma pathogenesis
33. Human immunodeficiency virus tat modulates the FIk-1/KDR receptor, mitogen-activated protein kinases, and components of focal adhesion in Kaposi's sarcoma cells
34. HIV-1 Tat induces the expression of the interleukin-6 (IL6) gene by binding to the IL6 leader RNA and by interacting with CAAT enhancer-binding protein beta (NF-IL6) transcription factors
35. Human immunodeficiency virus-1-tat induces matrix metalloproteinase-9 in monocytes through protein tyrosine phosphatase-mediated activation of nuclear transcription factor NF-kappaB
36. Recombinant human interferon alpha-A suppresses HTLV-III replication in vitro
37. Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant interferon alpha A
38. Synergistic interaction of 2′3′-dideoxycytidine (ddCyd) and recombinant interferon alpha A (rIFN-αA) on HIV-1 replication
39. Two-drug combinations of zidovudine, didanosine, and recombinant interferon-α A inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro
40. Synergy, activity and tolerability of zidovudine and interferon-alpha in patients with symptomatic HIV-1 infection: ACTG 068
41. Alpha interferon inhibits human herpesvirus 8 (HHV-8) reactivation in primary effusion lymphoma cells and reduces HHV-8 load in cultured peripheral blood mononuclear cells
42. Type I consensus IFN (IFN-con1) gene transfer into KSHV/HHV-8-infected BCBL-1 cells causes inhibition of viral lytic cycle activation via induction of apoptosis and abrogates tumorigenicity in SCID mice
43. Inflammatory cytokines and the reactivation of Kaposi's sarcoma-associated herpesvirus lytic replication
44. The KSHV/HHV-8-infected BCBL-1 lymphoma line causes tumors in SCID mice but fails to transmit virus to a human peripheral blood mononuclear cell graft
45. A possible role for interferon-alpha and activated natural killer cells in remission of AIDS-related Kaposi's sarcoma: In vitro studies
46. Characterization of in vitro culture of HIV-negative Kaposi's sarcoma-derived cells: In vitro responses to alfa interferon
47. Cytokine-activated human monocytes show differential cytotoxicity toward fresh and cultured Kaposi's sarcoma cells
48. Induction of circulating IL-1 receptor antoagnost by IFN treatment
49. Interferon-α induces circulating tumor necrosis factor receptor in humans
50. Consensus-interferon and platelet-derived growth factor adversely regulate proliferation and migration of Kaposi's sarcoma cells by control of c-myc expression
51. Microvascular injury in pathogenesis of interferon-induced necrosis of subcutaneous tumors in mice
52. Inhibition of angiogenesis by interferons: Effects on tumor- and lymphocyte-induced vascular responses
53. Progressive growth of infantile cutaneous hemangiomas is directly correlated with hyperplasia and angio genesis of adjacent epidermis and inversely correlated with expression of theendogenous angiogenesis inhibitor, IFN-beta
54. Molecular regulation of UVB-induced cutaneous angiogenesis
55. Regulation of neoplastic angiogenesis
56. Angiogenesis and cancer metastasis
57. Interferons alpha and beta down- regulate the expression of basic fibroblast growth factor in human carcino- mas
58. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carci- noma in mice by systemic interferon-alpha administration
59. Interferon-alpha-mediated down- regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule
60. Optimal biological dose of pegylated interferon-α (PEG IFN-α) inhibits angiogenesis and growth of human transitional cell carcinoma in the bladder of nude mice
61. Kaposi's sarcoma and the acquired immunodeficiency syndrome: Treatment with high and low doses of recombinant leukocyte A interferon
62. Recombinant alpha-2-interferon therapy for Kaposi's sarcoma associated with the acquired immunodeficiency syndrome
63. Interferon alfa-2a in the treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma
64. Human lymphoblastoid interferon treatment of Kaposi's sarcoma in the acquired immunodeficiency syndrome
65. Interferon alpha in the treatment of AIDSassociated Kaposi's sarcoma
66. Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi's sarcoma
67. Long-term follow-up of 120 patients with AIDS-related Kaposi's sarcoma treated with interferon alpha-2A
68. Treatment of Kaposi's sarcoma with interferon alfa-2b (Intron A)
69. Treatment of acquired immunodeficiency syndrome-related Kaposi's sarcoma with lymphoblastoid interferon
70. Interferon alfa-n1 Wellferon® in Kaposi's sarcoma: Single agent or combination with vinblastine
71. Anti-retroviral effects of interferon-α in AIDS-associated Kaposi's sarcoma
72. Clinical and virological effects of high-dose recombinant interferon-α in disseminated AIDS-related Kaposi's sarcoma
73. Immunological variables as predictors of prognosis in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome
74. Heterogeneity of epidemic Kaposi's sarcoma: Implications for therapy
75. 2-microglobulin, and neopterin serum levels in patients with Kaposi sarcoma and AIDS
76. Response of AIDS-related Kaposi's sarcoma to treatment with recombinant interferon alpha depends on the stage of underlying immunodeficiency
77. Zidovudine in patients with human immunodeficiency virus (HIV) infection and Kaposi sarcoma: A phase II randomized, placebo-controlled trial
78. Lack of activity of zidovudine in AIDS-associated Kaposi's sarcoma
79. Endogenous interferon and triglyceride concentrations to assess response to zidovudine in AIDS and advance AIDS-related complex
80. Surrogate markers for survival in patients with AIDS and AIDS-related complex
81. Multiple effects of interferon on the replication of human immunodeficiency virus type 1
82. Interferon-α with zidovudine: Safety, tolerance, and clinical and virologic effects in patients with Kaposi's sarcoma associated with the acquired immunodeficiency syndrome (AIDS)
83. A phase I study of recombinant human interferons-alfa-2a or human lymphoblastoid interferon alfa-n1 and concomitant zidovudine in patients with AIDS-related Kaposi's sarcoma
84. Combined zidovudine and interferon-α therapy in patients with Kaposi's sarcoma and the acquired immunodeficiency syndrome (AIDS)
85. A phase II study of recombinant human interferon-α2a and zidovudine in patients with AIDS-related Kaposi's sarcoma
86. Combined treatment with zidovudine and lymphoblast interferon-alpha in patients with HIV-related Kaposi's sarcoma
87. Prospective randomized trial of two dose levels of interferon alfa with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: A Canadian HIV Clinical Network study
88. Combined zidovudine and interferon-alpha treatment in patients with AIDS-associated Kaposi's sarcoma
89. Efficacy, safety, and tolerance of low-dose, long-term interferon-alpha 2b and zidovudine in early-stage AIDS-associated Kaposi's sarcoma
90. Low-dose interferon alpha combined with zidovudine in patients with AIDS-associated Kaposi's sarcoma
91. Long-term combined rIFN-alpha-2a and zidovudine therapy for HIV-associated Kaposi's sarcoma: Clinical consequences and side effects
92. Granutocyte-macrophage colony-stimulating factor mitigates the neutropenia of combined interferon alfa and zidovudine treatment of acquired immune deficiency syndrome-associated Kaposi's sarcoma
93. Interferonα-, zidovudine and granulocyte macrophage colony-stimulating factor: A phase I trial in patients with Kaposi's sarcoma associated with the acquired immunodeficiency syndrome (AIDS)
94. Multicenter, randomized, open-label, phase II trial of two doses of interferon (IFN)-α2b with didanosine (ddt) in HIV-related Kaposi's sarcoma: ACTG 206
95. Thalidomide increases both REM and stage 3-4 sleep in human adults: A preliminary study
96. The saga of thalidomide (concluded): Neuropathy to embryopathy, with case reports of congenital anomalies
97. Thalidomide in the treatment of lepra reaction
98. Current role of thalidomide in cancer treatment
99. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes
100. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset
101. Thalidomide exerts its inhibitory action on tumor necrosis factor by enhancing mRNA degradation
102. Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: Concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity
103. Binding of thalidomide to α 1 -acid glycoprotein may be involved in its inhibition of tumor necrosis factor production
104. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum
105. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis
106. Thalidomide-induced antigen-specific immune stimulation in patients with human immunodeficiency virus type 1 and tuberculosis
107. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection
108. Thalidomide for the treatment of AIDS-associated wasting
109. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection
110. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogs which are potent inhibitors of TNF-α
111. Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients
112. Thalidomide inhibits the replication of human immunodeficiency virus type 1
113. Effects of thalidomide on HIV-associated wasting syndrome: A randomized, double-blind, placebo-controlled clinical trial
114. Thalidomide is an inhibitor of angiogenesis
115. Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor
116. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent
117. Thalidomide and a thalidomide analogue inhibit endothelial cell proliferation in vitro
118. Inhibition of NFκB activity by thalidomide through suppression of IκB kinase activity
119. Mechanism of action in thalidomide teratogenesis
120. Regression of AIDS-related Kaposi's sarcoma during therapy with thalidomide
121. Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titre
122. Activity of thalidomide in AIDS-related Kaposi's sarcoma
123. Phase I trial of thalidomide in AIDS-related Kaposi's sarcoma